MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Taysha Gene Therapies Operating Expenses 2011-2025 | TSHA
Annual Operating Expenses Taysha Gene Therapies
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 99.8 M | 87.9 M | 165 M | 173 M | 43 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 173 M | 43 M | 114 M |
Quarterly Operating Expenses Taysha Gene Therapies
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 34 M | 28.7 M | 23.7 M | - | 27.7 M | 22.4 M | 27.7 M | - | 21 M | 25.8 M | 21.3 M | - | 25.5 M | 33.4 M | 49.7 M | - | 50.7 M | 40.8 M | 32.1 M | - | 15 M | 4.01 M | 5.58 M | 1.12 M | 31 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 50.7 M | 31 K | 24.5 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
Arbutus Biopharma Corporation
ABUS
|
96.2 M | $ 4.76 | -0.69 % | $ 790 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
92.7 M | $ 3.03 | -0.33 % | $ 234 M |  USA |
 |
Aeglea BioTherapeutics
AGLE
|
209 M | - | - | $ 1.01 B | USA |
 |
Alpine Immune Sciences
ALPN
|
88.2 M | - | - | $ 2.17 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
14 M | $ 0.22 | 23.77 % | $ 479 M |  Israel |
 |
AlloVir
ALVR
|
65.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
20.7 M | $ 1.17 | - | $ 6.38 M |  China |
 |
Ampio Pharmaceuticals
AMPE
|
9.57 M | - | -11.43 % | $ 502 K | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Celldex Therapeutics
CLDX
|
58.1 M | $ 26.37 | -1.71 % | $ 1.7 M | USA |
 |
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Cellectar Biosciences
CLRB
|
15.3 M | $ 2.55 | -7.79 % | $ 31.2 M | USA |
 |
Ascendis Pharma A/S
ASND
|
338 M | $ 208.21 | -2.16 % | $ 5 B |  Danmark |
 |
Aptevo Therapeutics
APVO
|
-31.8 M | $ 0.59 | -36.45 % | $ 163 K | USA |
 |
Alterity Therapeutics Limited
ATHE
|
16.7 M | $ 3.16 | 2.1 % | $ 7.6 B |  Australia |
 |
BioVie
BIVI
|
18.1 M | $ 1.22 | -3.94 % | $ 1.8 M | USA |
 |
Athersys
ATHX
|
79.8 M | - | 3.77 % | $ 22.4 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Avenue Therapeutics
ATXI
|
5.21 K | - | -52.27 % | $ 4.45 M | USA |
 |
ARCA biopharma
ABIO
|
88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
AVROBIO
AVRO
|
71.7 M | - | 1083.1 % | $ 745 M | USA |
 |
Acasti Pharma
ACST
|
24.4 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
141 M | - | -15.15 % | $ 60.3 M | Britain |
 |
BioDelivery Sciences International
BDSI
|
106 M | - | -4.8 % | $ 255 M | USA |
 |
Albireo Pharma
ALBO
|
163 M | - | -0.23 % | $ 916 M | USA |
 |
BioNTech SE
BNTX
|
512 M | $ 94.44 | -0.62 % | $ 27.2 B | Germany |
 |
Dynavax Technologies Corporation
DVAX
|
137 M | $ 15.38 | - | $ 2 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
168 M | $ 26.88 | 0.26 % | $ 1.3 B | USA |
 |
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Anika Therapeutics
ANIK
|
51.6 M | $ 9.54 | 0.65 % | $ 140 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
28.5 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
152 M | - | -7.31 % | $ 87 M | USA |
 |
bluebird bio
BLUE
|
854 M | - | - | $ 546 M | USA |
 |
Eton Pharmaceuticals
ETON
|
22.3 M | $ 16.96 | -0.16 % | $ 435 M | USA |
 |
Evogene Ltd.
EVGN
|
28 M | $ 1.01 | -3.81 % | $ 27.9 M | Israel |
 |
Arena Pharmaceuticals
ARNA
|
427 M | - | -6.81 % | $ 3.04 B | USA |
 |
Exelixis
EXEL
|
598 M | $ 46.29 | -0.47 % | $ 13.4 B | USA |
 |
Acer Therapeutics
ACER
|
24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Calithera Biosciences
CALA
|
125 M | - | -10.95 % | $ 876 K | USA |
 |
Axon Enterprise
AXON
|
1.18 B | $ 585.38 | -0.98 % | $ 44.3 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M | Israel |
|
Foghorn Therapeutics
FHTX
|
125 M | $ 5.37 | -0.56 % | $ 295 M | USA |
 |
Aytu BioScience
AYTU
|
53.7 M | $ 2.47 | -2.57 % | $ 15.5 M | USA |
 |
AstraZeneca PLC
AZN
|
17.6 B | $ 92.54 | 0.1 % | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | USA |
 |
Catalyst Biosciences
CBIO
|
176 M | $ 12.42 | 0.36 % | $ 818 M | USA |